BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9115587)

  • 1. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses.
    Tada M; Iggo RD; Waridel F; Nozaki M; Matsumoto R; Sawamura Y; Shinohe Y; Ikeda J; Abe H
    Mol Carcinog; 1997 Mar; 18(3):171-6. PubMed ID: 9115587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
    Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM
    Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
    Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
    Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Kordek R; Liberski PP
    Pol J Pathol; 1997; 48(4):221-4. PubMed ID: 9529927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
    Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T
    Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
    Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
    Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis of pediatric astrocytic tumors.
    Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
    Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
    Ren ZP; Olofsson T; Qu M; Hesselager G; Soussi T; Kalimo H; Smits A; Nistér M
    J Neuropathol Exp Neurol; 2007 Oct; 66(10):944-54. PubMed ID: 17917588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
    Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
    Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mutations of p53 gene in 41 cases of human brain gliomas].
    Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
    Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of p53 mutations on prognosis of patients with glioblastoma.
    Shiraishi S; Tada K; Nakamura H; Makino K; Kochi M; Saya H; Kuratsu J; Ushio Y
    Cancer; 2002 Jul; 95(2):249-57. PubMed ID: 12124823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethnicity delineates different genetic pathways in malignant glioma.
    Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
    Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the p53 protein in a spectrum of astrocytic tumours.
    Ellison DW; Gatter KC; Steart PV; Lane DP; Weller RO
    J Pathol; 1992 Dec; 168(4):383-6. PubMed ID: 1336544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal expansion of p53 mutant cells is associated with brain tumour progression.
    Sidransky D; Mikkelsen T; Schwechheimer K; Rosenblum ML; Cavanee W; Vogelstein B
    Nature; 1992 Feb; 355(6363):846-7. PubMed ID: 1311419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 10 and 17 deletions and p53 gene mutations in Thai patients with astrocytomas.
    Put-Ti-Noi S; Petmitr S; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
    Oncol Rep; 2004 Jan; 11(1):207-11. PubMed ID: 14654927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression as exemplified by human astrocytic tumors.
    Collins VP
    Semin Cancer Biol; 1999 Aug; 9(4):267-76. PubMed ID: 10448114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
    Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.